| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | 24005 |
| Drug | Fezolinetant |
| Brand | Veoza™ |
| Indication | Fezolinetant is indicated for the treatment of moderate to severe vasomotor symptoms associated with menopause. |
| Assessment Process | |
| Rapid review commissioned | 09/02/2024 |
| Rapid review completed | 12/03/2024 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of fezolinetant compared with the current standard of care. |
| Full HTA commissioned by the HSE | 08/04/2024 |
| Pre-submission consultation with Applicant | 24/04/2024 |
| Full submission received from Applicant | 20/08/2025 |
| Preliminary review sent to Applicant | 08/12/2025 |
| NCPE assessment re-commenced | 16/01/2026 |
| Factual accuracy sent to Applicant | 27/03/2026 |
| NCPE assessment re-commenced | 07/04/2026 |
| NCPE assessment completed | 17/04/2026 |
| NCPE assessment outcome | The NCPE recommends that fezolinetant be considered for reimbursement if cost effectiveness can be improved relative to existing treatments. HRT is expected to provide more benefits, than fezolinetant, in individuals who can take HRT. Thus, the HSE may wish to implement prescribing guidelines should a decision be made to reimburse fezolinetant. |
Next steps
The NCPE Assessment Report, recommendation and Patient Organisation Submission, will be considered by the HSE when making their decision on reimbursement, while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
Further information on this process may be found here.